Skip to main content
NCBI home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 2000 Apr;91(4):410–415. doi: 10.1111/j.1349-7006.2000.tb00960.x

Clinicopathological Significance of Expression of CD44 Variants in Head and Neck Squamous Cell Carcinoma

Minoru Kanke 1, Masato Fujii 1,✉, Kaori Kameyama 2, Jin Kanzaki 1, Yutaka Tokumaru 1, Yorihisa Imanishi 1, Toshiki Tomita 1, Yasuhiro Matsumura 3
PMCID: PMC5926470  PMID: 10804289

Abstract

Splice variants of the cell surface glycoprotein CD44 have been reported to be associated with the progression of various human tumors. The aim of this study is to determine the correlation between the expression of CD44 isoforms, especially CD44 variant 2 (CD44v2), and the clinicopathological features of head and neck squamous cell carcinomas (HNSCCs). The expression of CD44 isoforms was evaluated immunohistochemically in paraffin‐embedded tissues from 89 primary lesions, using monoclonal antibodies against CD44 standard (CD44st), CD44 variant 6 (CD44v6) and CD44v2. Cancer tissues from 89 (100%), 85 (95.5%) and 59 (66.3%) patients showed positive immunoreactivity for CD44st, CD44v6 and CD44v2, respectively. A significant correlation was observed between the down‐regulation of CD44v2 and poorer differentiation of the tumor cells (P=0.02). We could not find any significant correlation between the expression of CD44v2 and T stage or N stage (lymph node status). However, the rate of positive cervical lymph node metastasis tended to increase with reduced expression of CD44v2 (P=0.08). Down‐regulation of CD44v2 expression was correlated with shorter overall survival (P=0.01). Furthermore, Cox's multivariate analysis revealed that only CD44v2 expression and lymph node status were independent prognostic factors. These findings suggest that down‐regulation of CD44v2 expression may be one of the biological markers for the degree of malignancy in HNSCCs.

Keywords: CD44 variant, Head and neck squamous cell carcinoma, Immunohistochemistry, Prognostic factor, Biological marker

Full Text

The Full Text of this article is available as a PDF (485.0 KB).

REFERENCES

  • 1. ) Haynes , B. F. , Telen , M. J. , Hale , L. P. and Denning , S. M.CD44—a molecule involved in leukocyte adherence and T‐cell activation . Immunol. Today , 10 , 423 – 428 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Streit , M. , Schmidt , R. , Hilgenfeld , R. U. , Thiel , E. and Kreuser , E. D.Adhesion receptors in malignant transformation and dissemination of gastrointestinal tumors . Recent Results Cancer Res. , 142 , 19 – 50 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Jalkanen , S. , Bargatze , R. F. , de los Toyos , J. and Butcher , E. C.Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85–95‐kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells . J. Cell Biol. , 105 , 983 – 990 ( 1987. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. ) Arch , R. , Wirth , K. , Hofmann , M. , Ponta , H. , Matzku , S. , Herrlich , P. and Zöller , M.Participation in normal immune responses of a metastasis‐inducing splice variant of CD44 . Science , 257 , 682 – 685 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 5. ) Günthert , U. , Hofmann , M. , Rudy , W. , Reber , S. , Zöller , M. , Haußmann , I. , Matzku , S. , Wenzel , A. , Ponta , H. and Herrlich , P.A new variant glycoprotein CD44 confers metastatic potential to rat carcinoma cells . Cell , 65 , 13 – 24 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 6. ) Matsumura , Y. , Hanbury , D. , Smith , J. and Tarin , D.Noninvasive detection of malignancy by identification of unusual CD44 gene activity in exfoliated cancer cells . Br. Med. J. , 308 , 619 – 624 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. ) Matsumura , Y. , Sugiyama , M. , Matsumura , S. , Hayle , A. J. , Robinson , P. , Smith , J. C. and Tarin , D.Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities . J. Pathol. , 177 , 11 – 20 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) Matsumura , Y. and Tarin , D.Significance of CD44 gene products for cancer diagnosis and disease evaluation . Lancet , 340 , 1053 – 1058 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 9. ) Herrlich , P. , Zoller , M. , Pals , S. T. and Ponta , H.CD44 splice variants: metastases meet lymphocytes . Immunol. Today , 14 , 395 – 399 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 10. ) Mayer , B. , Jauch , K. W. , Günthert , U. , Figdor , C. G. , Schildberg , F. W. , Funke , I. and Johnson , J. P.De‐novo expression of CD44 and survival in gastric cancer . Lancet , 342 , 1019 – 1022 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 11. ) Mulder , J. W. , Kruyt , P. M. , Sewnath , M. , Oosting , J. , Seldenrijk , C. A. , Weidema , W. F. , Offerhaus , G. J. and Pals , S. T.Colorectal cancer prognosis and expression of exon‐v6‐containing CD44 proteins . Lancet , 344 , 1470 – 1472 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 12. ) Yamaguchi , A. , Urano , T. , Goi , T. , Saito , M. , Takeuchi , K. , Hirose , K. , Nakagawara , G. , Shiku , H. and Furukawa , K.Expression of a CD44 variant containing exons 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients . J. Clin. Oncol. , 14 , 1122 – 1127 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 13. ) Kaufmann , M. , Heider , K. H. , Sinn , H. P. , von Minckwitz , G. , Ponta , H. and Herrlich , P.CD44 variant exon epitopes in primary breast cancer and length of survival . Lancet , 345 , 615 – 619 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 14. ) Stauder , R. , Eisterer , W. , Thaler , J. and Günthert , U.CD44 variant isoforms in non‐Hodgkin's lymphoma: a new independent prognostic factor . Blood , 85 , 2885 – 2899 ( 1995. ). [PubMed] [Google Scholar]
  • 15. ) Tokue , Y. , Matsumura , Y. , Katsumata , N. , Watanabe , T. , Tarin , D. and Kakizoe , T.CD44 variant isoform expression and breast cancer prognosis . Jpn. J. Cancer Res. , 89 , 283 – 290 ( 1998. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. ) Gotoda , T. , Matsumura , Y. , Kondo , H. , Saitoh , D. , Shimada , Y. , Kosuge , T. , Kanai , Y. and Kakizoe , T.Expression of CD44 variants and its association with survival in pancreatic cancer . Jpn. J. Cancer Res. , 89 , 1033 – 1040 ( 1998. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. ) Favrot , M. C. , Combaret , V. and Lasset , C.CD44—a new prognostic marker for neuroblastoma . N. Engl. J. Med. , 329 , 1965 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 18. ) Spafford , M. F. , Koeppe , J. , Pan , Z. , Archer , P. G. , Meyers , A. D. and Franklin , W. A.Correlation of tumor markers p53, bcl‐2, CD34, CD44H, CD44v6, and Ki‐67 with survival and metastasis in laryngeal squamous cell carcinoma . Arch. Otolaryngol. Head Neck Surg. , 122 , 627 – 632 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 19. ) Gotoda , T. , Matsumura , Y. , Kondo , H. , Ono , H. , Kanamoto , A. , Kato , H. , Watanabe , H. , Tachimori , Y. , Nakanishi , Y. and Kakizoe , T.Expression of CD44 variants and prognosis in esophageal squamous cell carcinoma . Gut , 46 , 9 – 14 ( 2000. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. ) Borgya , A. , Woodman , A. C. , Sugiyama , M. , Donie , F. , Kopetzki , E. , Matsumura , Y. and Tarin , D.Isolation and characterisation of antibodies which specifically recognise the peptide encoded by exon 7 (v2) of the human CD44 gene . J. Clin. Pathol. Mol. Pathol. , 48 , M241 – 250 ( 1995. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. ) Kaplan , E. L. and Meier , P.Non parametric estimation from incomplete observation . J. Am. Stat. Assoc. , 53 , 457 – 481 ( 1958. ). [Google Scholar]
  • 22. ) Cox , D. R.Regression models and life tables . J. R. Stat. Soc. , 34 , 187 – 220 ( 1972. ). [Google Scholar]
  • 23. ) Soukka , T. , Salmi , M. , Joensuu , H. , Häkkinen , L. , Sointu , P. , Koulu , L. , Kalimo , K. , Klemi , P. , Grenman , R. and Jalkanen , S.Regulation of CD44v6‐containing isoforms during proliferation of normal and malignant epithelial cells . Cancer Res. , 57 , 2281 – 2289 ( 1997. ). [PubMed] [Google Scholar]
  • 24. ) Bahar , R. , Kunishi , M. , Kayada , Y. and Yoshiga , K.CD44 variant 6 (CD44v6) expression as a progression marker in benign, premalignant and malignant oral epithelial tissues . Int. J. Oral Maxillofac. Surg. , 26 , 443 – 446 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 25. ) Kunishi , M. , Kayada , Y. and Yoshiga , K.Down‐regulated expression of CD44 variant 6 in oral squamous cell carcinomas and its relationship to regional lymph node metastasis . Int. J. Oral Maxillofac. Surg. , 26 , 280 – 283 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 26. ) Heider , K. H. , Sproll , M. , Susani , S. , Patzelt , E. , Beaumier , P. , Ostermann , E. , Ahorn , H. and Adolf , G. R.Characterization of a high‐affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas . Cancer Immunol. Immunother. , 43 , 245 – 253 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 27. ) Herold‐Mende , C. , Seiter , S. , Born , A. I. , Patzelt , E. , Schupp , M. , Zöller , J. , Bosch , F. X. and Zöller , M.Expression of CD44 splice variants in squamous epithelia and squamous cell carcinomas of the head and neck . J. Pathol. , 179 , 66 – 73 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 28. ) Fujita , N. , Yaegashi , N. , Ide , Y. , Sato , S. , Nakamura , M. , Ishiwata , I. and Yajima , A.Expression of CD44 in normal human versus tumor endometrial tissues: possible implication of reduced expression of CD44 in lymph‐vascular space involvement of cancer cells . Cancer Res. , 54 , 3922 – 3928 ( 1994. ). [PubMed] [Google Scholar]
  • 29. ) Bourguignon , L. Y. , Gunja‐Smith , Z. , Iida , N. , Zhu , H. B. , Young , L. J. , Muller , W. J. and Cardiff , R. D.CD44v3,8–10 is involved in cytoskeleton‐mediated tumor cell migration and matrix metalloproteinase (MMP‐9) association in metastatic breast cancer cells . J. Cell Physiol. , 176 , 206 – 215 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 30. ) Okamoto , I. , Kawano , Y. , Tsuiki , H. , Sasaki , J. , Nakao , M. , Matsumoto , M. , Suga , M. , Ando , M. , Nakajima , M. and Saya , H.CD44 cleavage induced by a membrane‐associated metalloprotease plays a critical role in tumor cell migration . Oncogene , 18 , 1435 – 1446 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 31. ) Takahashi , K. , Eto , H. and Tanabe , K. K.Involvement of CD44 in matrix metalloproteinase‐2 regulation in human melanoma cells . Int. J. Cancer , 80 , 387 – 395 ( 1999. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES